Biora Therapeutics Inc (BIOR)vsMerck & Company Inc (MRK)
BIOR
Biora Therapeutics Inc
$0.22
0.00%
HEALTHCARE · Cap: $994,990
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7647342% more annual revenue ($65.77B vs $860,000). MRK leads profitability with a 13.6% profit margin vs 0.0%. BIOR trades at a lower P/E of 0.6x. MRK earns a higher WallStSmart Score of 50/100 (D+).
BIOR
Hold38
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIOR.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Revenue surging 15800.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOR
The strongest argument for BIOR centers on P/E Ratio, Revenue Growth, Debt/Equity. Revenue growth of 15800.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BIOR
The primary concerns for BIOR are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BIOR profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BIOR carries more volatility with a beta of 1.28 — expect wider price swings.
BIOR is growing revenue faster at 15800.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biora Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?